Rituximab efficiently depletes B cells in lung tumors and normal lung tissue [version 1; referees: 2 approved]

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue [version 1; referees: 2 approved]

Rituximab is a monoclonal antibody that targets the CD20 B-cell-specific antigen and is widely used as therapy for B-cell lymphoma. Since rituximab depletes both malignant and normal B cells, it is increasingly being used to treat various conditions in which normal B cells have a pathogenic role, su...

Full description

Bibliographic Details
Main Authors: Albane Joly-Battaglini, Clara Hammarström, Branislava Stankovic, Henrik Aamodt, Johan Stjärne, Odd Terje Brustugun, Åslaug Helland, Inger Øynebråten, Alexandre Corthay
Format: Article
Language:English
Published: F1000 Research Ltd 2016-01-01
Series:F1000Research
Subjects:
Cancer Therapeutics
Lymphomas & Myelomas
Online Access:http://f1000research.com/articles/5-38/v1

Similar Items

Similar Items